Early Higher Plasma Regorafenib Concentration Predicts Shorter PFS in Japanese Patients With mCRC

ABSTRACT The pharmacokinetics of regorafenib and its active metabolites, M2 and M5, vary widely among individual patients. However, the relationship between these plasma concentrations and therapeutic efficacy remains unclear. Patients with metastatic colorectal cancer (mCRC) receiving regorafenib a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Kazuo Kobayashi, Takeru Wakatsuki, Erika Sugiyama, Eiji. Shinozaki, Masataka Tajima, Mariko Ogura, Keisho Chin, Akira Ooki, Hiroki Osumi, Shota Fukuoka, Shohei Udagawa, Keitaro Shimozaki, Takeshi Aoyama, Yasuhiro Nakano, Kazuyoshi Kawakami, Wataru Suzuki, Takashi Yokokawa, Hitoshi Sato, Masakazu Yamaguchi, Kensei Yamaguchi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2025-11-01
coleção:	Clinical and Translational Science
Assuntos:	neutrophil to lymphocyte ratio pharmacokinetics polymorphisms progression‐free survival regorafenib
Acesso em linha:	https://doi.org/10.1111/cts.70386
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!